Literature DB >> 8389809

Prophylactic and therapeutic vaccination against a mucosal papillomavirus.

M S Campo1, G J Grindlay, B W O'Neil, L M Chandrachud, G M McGarvie, W F Jarrett.   

Abstract

Papillomaviruses are ubiquitous DNA viruses affecting humans and animals and causing a variety of tumours of mucosal and cutaneous epithelia. Some of these lesions, particularly those affecting mucosal epithelia, can progress to squamous cell carcinomas. Prevention or cure of viral infection would ultimately lead to a decrease in the incidence of papillomavirus-associated cancers. Using recombinant proteins, we have developed prophylactic and therapeutic vaccines against bovine papillomavirus type 4, a mucosal papillomavirus implicated in cancer of the alimentary canal in cattle; similar possibilities exist for the human mucosal papillomaviruses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389809     DOI: 10.1099/0022-1317-74-6-945

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

1.  Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Authors:  Joshua W Wang; Subhashini Jagu; Wai-Hong Wu; Raphael P Viscidi; Anne Macgregor-Das; Jessica M Fogel; Kihyuck Kwak; Sai Daayana; Henry Kitchener; Peter L Stern; Patti E Gravitt; Cornelia L Trimble; Richard B S Roden
Journal:  Clin Vaccine Immunol       Date:  2015-05-13

Review 2.  Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2013-02       Impact factor: 5.217

3.  Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression.

Authors:  R Selvakumar; A Schmitt; T Iftner; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 4.  Second-generation prophylactic HPV vaccines: successes and challenges.

Authors:  Mitchell Tyler; Ebenezer Tumban; Bryce Chackerian
Journal:  Expert Rev Vaccines       Date:  2013-12-18       Impact factor: 5.217

Review 5.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits.

Authors:  Antonia Radaelli; Eleana Pozzi; Sole Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen
Journal:  J Transl Med       Date:  2010-04-21       Impact factor: 5.531

Review 7.  HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.

Authors:  Luciano Mariani; Aldo Venuti
Journal:  J Transl Med       Date:  2010-10-27       Impact factor: 5.531

8.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

Review 9.  Reflections on viruses and cancer.

Authors:  C Darcel
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

10.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.